Published in Am J Gastroenterol on December 07, 2010
ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol (2015) 3.22
Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology (2015) 1.21
Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study. BMC Cancer (2012) 1.19
BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol (2015) 1.17
Screening for oesophageal cancer. Nat Rev Clin Oncol (2012) 1.13
Screening for Barrett's Esophagus. Gastroenterology (2015) 1.11
Evidence-based endoscopic management of Barrett's esophagus. Gastroenterol Rep (Oxf) (2014) 0.84
Esophageal cancer in Canada: trends according to morphology and anatomical location. Can J Gastroenterol (2012) 0.84
Gastroesophageal reflux disease and tooth erosion. Int J Dent (2011) 0.83
Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol (2014) 0.81
Screening for Barrett's esophagus: results from a population-based survey. Dig Dis Sci (2014) 0.79
Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease after a negative screening endoscopy. Clin Gastroenterol Hepatol (2014) 0.78
Effects of refluxate pH values on duodenogastroesophageal reflux-induced esophageal adenocarcinoma. World J Gastroenterol (2011) 0.78
Editorial: should women with heartburn undergo screening upper endoscopy for prevention of cancer? Am J Gastroenterol (2011) 0.76
Risk Factors for Barrett's Oesophagus. Gastrointest Tumors (2016) 0.75
Are we ready for gender-based guidelines for Barrett's esophagus screening? Gastroenterology (2011) 0.75
Diagnostics and Early Diagnosis of Esophageal Cancer. Viszeralmedizin (2015) 0.75
The Race-Specific Incidence of Esophageal Squamous Cell Carcinoma in Individuals With Exposure to Tobacco and Alcohol. Am J Gastroenterol (2016) 0.75
Prevalence and Predictors of Gastroesophageal Reflux Complications in Community Subjects. Dig Dis Sci (2016) 0.75
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 8.51
Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol (2008) 7.94
Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med (2003) 7.73
Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol (1998) 4.68
Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol (2002) 3.94
A theory of medical decision making and health: fuzzy trace theory. Med Decis Making (2008) 3.67
Endoscopic video-autofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barrett's esophagus. Gastrointest Endosc (2006) 3.60
A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology (2004) 3.50
Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology (2002) 3.28
Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol (2009) 3.04
Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer (2001) 3.02
Gastroesophageal reflux among different racial groups in the United States. Gastroenterology (2004) 2.87
Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology (2007) 2.86
Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol (2005) 2.36
Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut (2007) 2.28
Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol (2006) 2.26
Detection and classification of the mucosal and vascular patterns (mucosal morphology) in Barrett's esophagus by using narrow band imaging. Gastrointest Endosc (2006) 2.22
Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer (2003) 2.03
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control (2000) 2.00
Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol (2007) 1.96
Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc (2008) 1.96
American Gastroenterological Association medical position statement: Role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology (2005) 1.43
Prevalence of gastro-oesophageal reflux symptoms and the influence of age and sex. Scand J Gastroenterol (2004) 1.23
Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther (2010) 1.16
Influence of malpractice history on the practice of screening and surveillance for Barrett's esophagus. Am J Gastroenterol (2007) 1.16
Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer (2002) 1.16
Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life-a population-based study. J Clin Gastroenterol (2009) 1.13
Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One (2008) 1.12
Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. JAMA (2000) 0.94
Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without barrett mucosa. Arch Surg (2005) 0.94
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol (2009) 12.16
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med (2012) 4.51
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Endoscopic Transpapillary Gallbladder Stent Placement Is Safe and Effective in High-Risk Patients Without Cirrhosis. Dig Dis Sci (2014) 2.62
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol (2008) 2.39
Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol (2006) 2.38
AGA Institute review of endoscopic sedation. Gastroenterology (2007) 2.35
Prediction of Barrett's esophagus among men. Am J Gastroenterol (2013) 2.22
National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med (2009) 2.19
Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc (2008) 2.09
Exploring utilities and outcomes with infliximab therapy. Clin Gastroenterol Hepatol (2006) 2.04
Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc (2008) 1.96
A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol (2009) 1.81
Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol (2009) 1.74
Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer (2007) 1.68
Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl (2011) 1.67
The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology (2012) 1.65
A cost-utility analysis of secondary prophylaxis for variceal hemorrhage. Am J Gastroenterol (2004) 1.51
National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology (2009) 1.48
Association between ambient ultraviolet radiation and risk of esophageal cancer. Am J Gastroenterol (2012) 1.46
Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol (2008) 1.45
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology (2011) 1.44
Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers. Am J Gastroenterol (2008) 1.38
Esophageal cancer in Indigenous Australians in Far North Queensland. J Gastroenterol Hepatol (2009) 1.37
Growth of ambulatory surgical centers, surgery volume, and savings to medicare. Am J Gastroenterol (2013) 1.36
Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care (2010) 1.35
American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology (2013) 1.32
Intrasphincteric botulinum toxin versus pneumatic balloon dilation for treatment of primary achalasia. J Clin Gastroenterol (2003) 1.27
Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol (2007) 1.25
Women patients' preference for women physicians is a barrier to colon cancer screening. Gastrointest Endosc (2005) 1.20
Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc (2011) 1.18
Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int J Cancer (2008) 1.10
Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus. Gastroenterology (2013) 1.09
Cost-effective treatment of patients with symptomatic cholelithiasis and possible common bile duct stones. J Am Coll Surg (2011) 1.07
EMR for early stage esophageal cancer: setting the stage for improved patient outcomes. Gastrointest Endosc (2003) 1.07
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J (2009) 1.03
Endoscopic ultrasound-guided fine needle aspiration of the pancreas. Diagnostic utility and accuracy. Acta Cytol (2003) 1.03
Pragmatic classification of superficial neoplastic colorectal lesions. Gastrointest Endosc (2009) 1.02
Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol (2005) 1.01
Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS (2015) 0.99
Why you should care about screening flexible sigmoidoscopy. N Engl J Med (2012) 0.99
Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. Gut (2013) 0.98
Acute pancreatitis after EUS-guided FNA of solid pancreatic masses: a pooled analysis from EUS centers in the United States. Gastrointest Endosc (2004) 0.98
Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data. Am J Gastroenterol (2013) 0.96
Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2010) 0.96
Management of obscure occult gastrointestinal bleeding: a cost-minimization analysis. Clin Gastroenterol Hepatol (2008) 0.95
Solaria use in Queensland, Australia. Aust N Z J Public Health (2006) 0.94
Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy. J Gastrointest Oncol (2012) 0.94
On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol (2007) 0.94
The Queensland Cancer Risk Study: behavioural risk factor results. Aust N Z J Public Health (2006) 0.93
Quality indicators for EGD. Gastrointest Endosc (2014) 0.92
Quality indicators for ERCP. Gastrointest Endosc (2014) 0.92
Prevalence and correlates of multiple cancer risk behaviors in an Australian population-based survey: results from the Queensland Cancer Risk Study. Cancer Causes Control (2008) 0.90
Race and inflammatory bowel disease in an urban healthcare system. Dig Dis Sci (2010) 0.90
In search of quality colonoscopy. Gastroenterology (2008) 0.89
PANDA cyst-fluid analysis: eats, shoots and leaves? Gastrointest Endosc (2009) 0.88
Making cost-effectiveness analyses clinically relevant: the effect of provider expertise and biliary disease prevalence on the economic comparison of alternative diagnostic strategies. Acad Radiol (2003) 0.88
Quality indicators for EGD. Am J Gastroenterol (2014) 0.87
A clinical and economic evaluation of endoscopic ultrasound for patients at risk for familial pancreatic adenocarcinoma. Pancreatology (2007) 0.87
The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther (2013) 0.86
Sun protection and low levels of vitamin D: are people concerned? Cancer Causes Control (2007) 0.86
EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc (2003) 0.86
Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol (2005) 0.86
A survey of expert follow-up practices after successful endoscopic eradication therapy for Barrett's esophagus with high-grade dysplasia and intramucosal adenocarcinoma. Gastrointest Endosc (2013) 0.86
Clinical yield of diagnostic endoscopic retrograde cholangiopancreatography in orthotopic liver transplant recipients with suspected biliary complications. Liver Transpl (2012) 0.84
Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med (2003) 0.84
NSAIDs without a prescription: over-the-counter access, under-counted risks. Am J Gastroenterol (2002) 0.84
Anesthesia for colonoscopy: too much of a good thing? JAMA Intern Med (2013) 0.83
New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clin Gastroenterol Hepatol (2009) 0.83
Non-English speakers attend gastroenterology clinic appointments at higher rates than English speakers in a vulnerable patient population. J Clin Gastroenterol (2009) 0.83
Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med (2002) 0.83
Endoscopic findings and clinical outcomes in ventricular assist device recipients with gastrointestinal bleeding. Dig Dis Sci (2011) 0.82
Risk stratification in upper gastrointestinal bleeding. J Clin Gastroenterol (2007) 0.82
HPV vaccination: what do Queensland parents think? Aust N Z J Public Health (2007) 0.82
Initial experience with an electronic radial array echoendoscope: randomized comparison with a mechanical sector scanning echoendoscope in humans. Gastrointest Endosc (2002) 0.81
Quality indicators for ERCP. Am J Gastroenterol (2014) 0.81
Rating access to health care: Are there differences according to geographical region? Aust N Z J Public Health (2008) 0.80
Nonmucinous cystic pancreatic neoplasms. Gastrointest Endosc Clin N Am (2002) 0.80
New advances in pancreatic imaging. Curr Opin Gastroenterol (2006) 0.80
Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome. J Clin Gastroenterol (2014) 0.80
Time to burn? Endoscopic ablation for Barrett's esophagus. Gastroenterology (2011) 0.79
Prevalence of BRAF and NRAS mutations in fast-growing melanomas. Pigment Cell Melanoma Res (2013) 0.79
Suspected choledocholithiasis: EUS, magnetic resonance cholangiopancreatography, or intraoperative cholecystectomy? Gastrointest Endosc (2002) 0.79
A new approach to estimation of the number of central synapse(s) included in the H-reflex. BMC Neurol (2005) 0.79
The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: item reduction and further validation. Qual Life Res (2014) 0.79
Computed tomography versus endoscopic ultrasonography for staging of pancreatic cancer. Ann Intern Med (2005) 0.79
Characteristics of men aged 50 years or older who do not take up skin self-examination following an educational intervention. J Am Acad Dermatol (2012) 0.79
Reliable gene expression measurements from fine needle aspirates of pancreatic tumors: effect of amplicon length and quality assessment. J Mol Diagn (2010) 0.79
Pancreatic cystic lesions. Curr Opin Gastroenterol (2010) 0.78
Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States. Am J Gastroenterol (2002) 0.78
Defining a clinically significant adverse impact of diagnosing Barrett's esophagus. J Clin Gastroenterol (2006) 0.78
AJC Editor's consensus: Selective and nonselective nonsteroidal anti-inflammatory drugs and cardiovascular risk. Am J Cardiol (2010) 0.78
Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis. Arthritis Rheum (2002) 0.78
A glossary of economic terms. Eur J Gastroenterol Hepatol (2004) 0.78